ENTBF Stock Chart & Stats
$0.04
$0.00(0.00%)
At close: 4:00 PM EDT
$0.04
$0.00(0.00%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.10
Previous CloseN/A
Volume17.00
Average Volume (3M)338.00
Market Cap
$544.36K
Enterprise Value$1.06M
Total Cash (Recent Filing)$321.83K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta5.88
Next Earnings
Mar 30, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding13,858,926
10 Day Avg. Volume738
30 Day Avg. Volume338
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)3.72
Price to Sales (P/S)0.00
P/FCF Ratio-3.83
Enterprise Value/Market Cap1.95
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.77
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetThe absence of reported debt limits interest obligations and reduces near-term solvency pressure. This gives management greater flexibility than a leveraged biotechnology peer, although the benefit remains dependent on controlling losses and preserving the company’s capital base.
Reduced Loss SeverityThe substantial reduction in losses from the 2021–2022 extremes indicates some improvement in financial discipline or operating scale. If maintained, lower losses could extend the company’s runway and reduce the pace at which its equity base is consumed.
Focused Therapeutic R&DA focused effort in psychedelic-assisted treatments gives Entheon a defined therapeutic mission rather than a broad, unfocused biotechnology strategy. Continued clinical and regulatory work could build specialized expertise and support eventual medical applications if candidates advance successfully.
Bears Say
No Recent RevenueThe absence of recent revenue shows that the company has not yet established a commercial operating base. Without recurring sales, funding for research and regulatory activity remains reliant on existing resources or future capital, making progress vulnerable to financing constraints.
Persistent UnprofitabilityRecurring operating and net losses demonstrate that the business has not reached sustainable profitability. Continued deficits can erode shareholder capital and limit the company’s ability to fund development internally, especially while revenue remains absent.
Ongoing Cash BurnPersistent negative operating and free cash flow means the company continues to consume cash rather than generate funding from operations. The renewed deterioration after earlier improvement increases dependence on external financing and may constrain the pace of development.
Entheon Biomedical News
ENTBF FAQ
What was Entheon Biomedical’s price range in the past 12 months?
Entheon Biomedical lowest stock price was <$0.01 and its highest was $0.10 in the past 12 months.
What is Entheon Biomedical’s market cap?
Entheon Biomedical’s market cap is $544.36K.
When is Entheon Biomedical’s upcoming earnings report date?
Entheon Biomedical’s upcoming earnings report date is Mar 30, 2027 which is in 155 days.
How were Entheon Biomedical’s earnings last quarter?
Entheon Biomedical released its earnings results on Jul 20, 2026. The company reported $0.013 earnings per share for the quarter.
Is Entheon Biomedical overvalued?
According to Wall Street analysts Entheon Biomedical’s price is currently Overvalued.
Does Entheon Biomedical pay dividends?
Entheon Biomedical does not currently pay dividends.
What is Entheon Biomedical’s EPS estimate?
Entheon Biomedical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Entheon Biomedical have?
Entheon Biomedical has 13,858,926 shares outstanding.
What happened to Entheon Biomedical’s price movement after its last earnings report?
Entheon Biomedical reported an EPS of $0.013 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Entheon Biomedical?
Currently, no hedge funds are holding shares in ENTBF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Entheon Biomedical
Entheon Biomedical Corp. operates as a biotechnology research and drug development company. It engages in developing and commercializing various N,N-dimethyltryptamine based psychedelic therapeutic products for treating addiction and substance use disorders. The company serves physicians, clinics, and licensed psychiatrists in Canada, the United States, and European Union. Entheon Biomedical Corp. is headquartered in Vancouver, Canada.
Technical Analysis
BetterLife Pharma
―
HAVN Life Sciences
―
MYND Life Sciences
―
Universal Ibogaine Inc
―
Mindbio Therapeutics Corp.
―